Literature DB >> 11028767

Serum eosinophil cationic protein in active and quiescent ulcerative colitis.

C J Pronk-Admiraal1, R K Linskens, A A Van Bodegraven, H A Tuynman, P C Bartels.   

Abstract

Inflammatory bowel disorders are characterized by an accumulation of eosinophilic granulocytes, mast cells, lymphocytes and neutrophilic granulocytes in the intestinal mucosa. The aim of this study was to examine the concentration of eosinophilic granulocytes in the blood of patients during active ulcerative colitis in comparison with patients during remission and apparently healthy control subjects. Besides counting, the activity grade of eosinophilic granulocytes has been studied by estimation of their degranulation product eosinophil cationic protein. Subjects with active ulcerative colitis could be distinguished from patients with quiescent ulcerative colitis by establishment of the eosinophil cationic protein concentration, neutrophilic granulocyte count, erythrocyte sedimentation rate, C-reactive protein and albumin concentration. After two weeks of corticosteroid treatment, serum eosinophil cationic protein concentrations and eosinophil counts in blood were significantly decreased. A decrease in blood eosinophil count was accompanied by a decrease in eosinophil cationic protein concentrations in serum in most subjects with ulcerative colitis. After twelve weeks of corticosteroid administration, serum albumin concentrations were significantly increased, whereas serum concentrations of C-reactive protein were significantly decreased. During treatment with corticosteroids, serum eosinophil cationic protein concentrations and blood eosinophil counts are appropriate laboratory markers to detect the effect of medication in the course of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028767     DOI: 10.1515/CCLM.2000.090

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  3 in total

1.  Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Stanisław Pieczarkowski; Kinga Kowalska-Duplaga; Zofia Grzenda-Adamek; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

Review 2.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

3.  Activated eosinophils in association with enteric nerves in inflammatory bowel disease.

Authors:  Claire M Smyth; Nadim Akasheh; Sara Woods; Elaine Kay; Ross K Morgan; Margaret A Thornton; Anthony O'Grady; Robert Cummins; Orla Sheils; Peter Smyth; Gerald J Gleich; Frank M Murray; Richard W Costello
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.